(Nasdaq: CMGE), a leading mobile game company in China.
" />
English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 13 October 2014, 19:00 HKT/SGT
Share:
China Mobile Games & Entertainment Group Fundamentals Still Solid; Buy into Dips

HONG KONG, Oct 13, 2014 - (ACN Newswire) - CICC maintain "BUY" rate and raise the target price by 32% from US$19 to US$25 on China Mobile Games and Entertainment Group Limited ("CMGE" or the "Company")
(Nasdaq: CMGE), a leading mobile game company in China.

3Q14 rev. close to high end of guidance, pipeline strong
CICC expect 3Q14 revenue to grow 245% YoY / 23% QoQ to Rmb338mn, and non-GAAP NI to grow 213% YoY / 24% QoQ to Rmb78mn. Strong results were helped by Super Hero, Tiantian Hero, and increasing revenue from self-developed card & board games.

Trends to watch
Winner in the consolidation of mobile game publishing business.
CICC see that CMGE has benefited from mobile game publisher consolidation and has been taking more and more market share. CICC favor CMGE's independent role as a mobile game publisher and believe industry growth coupled with market share gains can help CMGE deliver strong performance.

Strong 4Q14 pipeline to contribute to rapid growth in 2015.
CMGE launched CA (FPS) and The New Legend (APRG) in late September, both delivered monthly gross billings of over Rmb20mn. CMGE has a robust pipeline in 4Q14, CICC believe Feng Zhong Qi Yuan (the same IP as the popular TV drama), Age of Discovery, Naruto and One Piece are among the most awaited games.

Management concerns to disappear with smooth operations.
The market is over-concerned with CMGE's management issues. As the company performs well, market concerns will gradually be erased, and corporate restructure will prove to be more efficient as margins improve.

Valuation and recommendation
CMGE's share price was at one point 100% higher than the last call in August; though it experienced a pullback due to systematic risk, the current share price is still 18% higher than the initial coverage on August 5, 2014. CICC lower 2014 EPS by 11.5% to Rmb8.6 and increase 2015 EPS by 10.3% to 15.4. CICC believe the recent correction provides a good opportunity to buy and raise the target price by 32% from US$19 to US$25, as removed the management risk discount of 20% and raised 2015 earnings forecast by 8.3%. Maintain BUY rating. TP represents 2014/15 PER of 18x/10x.

Topic: Press release summary Sectors: Media & Marketing, Daily Finance, IT Individual, Daily News
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets  
Feb 6, 2026 17:45 HKT/SGT
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share  
Feb 6, 2026 17:01 HKT/SGT
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization  
Feb 6, 2026 16:34 HKT/SGT
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis  
Feb 6, 2026 14:17 HKT/SGT
Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025  
Feb 6, 2026 13:13 HKT/SGT
Mitsubishi Motors Launches the All-New Versa Van in the Philippine Market  
Friday, February 6, 2026 12:34:00 PM
Eternal Beauty Holdings Limited and Lane Crawford Debut Landmark Fragrance, Further Expanding Footprint in High-Margin Niche Fragrance Market  
Feb 6, 2026 12:21 HKT/SGT
Distinct Healthcare Successfully Listed on HKEX, Bolstered by Premium Customer Base and All-Star Cornerstone Investors  
Feb 6, 2026 11:44 HKT/SGT
Establishment of the World's First*1 Global Supply Chain to Introduce the Use of Renewable Plastics in Sony's High-Performance Products  
Friday, February 6, 2026 10:50:00 AM
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan  
Friday, February 6, 2026 10:31:00 AM
More Press release >>
 Events:
More events >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575